GE, Hologic will show full-field works in progressWith its acquisition of Instrumentarium completed on Oct. 9, GE Medical Systems (South Hall 4100) is poised to begin delivering advanced mammography applications, including
GE, Hologic will show full-field works in progress
With its acquisition of Instrumentarium completed on Oct. 9, GE Medical Systems (South Hall 4100) is poised to begin delivering advanced mammography applications, including tomosynthesis.
"With our in-house expertise and the patent, we are comfortable that we will be developing our tomosynthesis program quickly," said Laura Bakosh, general manager of women's healthcare for GE in the Americas.
The tuned aperture CT (TACT) 3D product developed by Instrumentarium is a stepping stone to full-field breast tomosynthesis. TACT obtains images from several angles as the x-ray source moves along the top of the breast. It uses a reference point located above the breast to calculate imaging geometry. GE's full-field digital tomosynthesis captures images from 11 positions as the x-ray tube navigates across a 50º arc. The technique reconstructs the images as 1-mm-thick planar scans with a pixel resolution of 100 mm throughout the breast.
A workstation optimized to display the results of tomosynthesis will accompany TACT 3D in the GE booth at the RSNA meeting.
Hologic (South Hall 2709) is also in the race to develop breast tomosynthesis. At the RSNA meeting, Hologic will demonstrate a work-in-progress tomosynthesis hardware and software package that can be added to the Selenia full-field digital mammography system. The package, slated for delivery around the world next year, acquires a full volume of data without increasing the x-ray dose beyond conventional screen-film or digital mammography levels.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.